Consonance-Hfw Acq Corp (SRZN) Stock Price, Quote & News

Company Profile

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat di...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 489 9000

Website: www.surrozen.com

Address:

171 Oyster Point Boulevard, Suite 400, South San Francisco, United States

LabPsycho Apr. 24 at 7:30 PM

$SRZN @Odintrading IMO, Nothing says BioGrifter's Wealth Transfer Vehicle Alert! like dumping more shares after a stock is down 80-90% from historic highs. Or the pre-pump by the Underwriters. Gross. Do they even have anything in the clinic?

1 · Reply

BuyoutBobby Apr. 24 at 6:07 PM

$SRZN TCG's portfolio company Neurona Therapeutics was acquired recently.

1 · Reply

BuyoutBobby Apr. 24 at 8:36 AM

$SRZN somebody bought a lot of shares in Q1 and reached over 5% ownership on April 22 and that's why they had to file this 13G document. https://www.sec.gov/Archives/edgar/data/1824893/000091957426002357/xslSCHEDULE_13G_X02/primary_doc.xml

0 · Reply

BuyoutBobby Apr. 23 at 8:09 PM

$SRZN the recent milestone that Boehringer Ingelheim reached with the GLP tox study is also derisking our drugs SZN-8141/8143 a bit because the WNT part of them is the same as SZN-413. So Boehringer Ingelheim helped us to increase the value of these drugs. They now have to make the decision if it makes sense to continue the development of SZN-413 even though there are better versions of it at Surrozen and they could go to a competitor. Boehringer Ingelheim has the advantage of working with Surrozen since 2022. They know the company and they know more about our drugs than any other company and they maybe already have knowledge if sustained release versions with Re-Vana's technology are possible. All other potential acquirers of Surrozen(Regeneron, Roche, Merck) also know that BI has this advantage and that could be a problem for them.

0 · Reply

BuyoutBobby Apr. 23 at 7:10 PM

$SRZN this post from January is more relevant now. I added new informations and discussed this with chatgpt again. New facts are that we are using the aflibercept sequence in SZN-8141/8143 and that BI reached the GLP tox milestone.

0 · Reply

Odintrading Apr. 22 at 2:03 PM

$SRZN I'm out. This is looking like a failed breakout. I don't like that TD Cowen is administering the ATM that went into effect and 3 weeks later initiates coverage. This thing can fall a long way with those warrants and the ATM now that TCG seems to be done buying

1 · Reply

BuyoutBobby Apr. 22 at 12:07 PM

$SRZN in September the results of Restoret's phase 2b/3 trial could be available. Positive results could increase the value of our drugs. A company like Boehringer Ingelheim has reasons to not wait until those results are out. They should try to acquire Surrozen beforehand or they risk to lose everything to a competitor. https://clinicaltrials.gov/study/NCT06571045

1 · Reply

Quantumup Apr. 21 at 12:21 PM

TD Cowen🏁 $SRZN at a Buy rating. $OCUL $EYPT MRK REGN RHHBY FDMT KOD TD Cowen said in its initiation report: Surrozen is developing multifunctional antibodies that leverage Wnt activation for vascular retinopathies. Leadi candidate SZN-8141 combines Wnt agonism with VEGF antagonism and an IND is expected in H2:26. We estimate SZN-8141 addresses a $5B+ opportunity in wAMD and DME. We expect SRZN to create much L-T shareholder value as its pipeline advances. We are initiating with a Buy rating.

0 · Reply

SocioCobb Apr. 16 at 1:32 PM

$SRZN 👍

2 · Reply

raticals Apr. 14 at 9:44 PM

$IMUX they had to do the reverse to get the $200 million in the first tranche. The reverse for $SRZN worked out awesome. Without the 200 million and they weren’t getting to the finish line so it is what it is.

0 · Reply

Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 4, 2026, 1:10 PM EST - 7 weeks ago

Surrozen Transcript: TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 4:05 PM EST - 2 months ago

Surrozen to Present at Upcoming Healthcare Investor Conference

Feb 23, 2026, 4:30 PM EST - 2 months ago

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 12, 2026, 1:30 PM EST - 2 months ago

Surrozen Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Dec 3, 2025, 3:25 PM EST - 5 months ago

Surrozen Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 9:30 AM EST - 5 months ago

Surrozen Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 4:05 PM EST - 5 months ago

Surrozen to Present at Upcoming Healthcare Investor Conferences

Nov 12, 2025, 9:30 AM EST - 5 months ago

Surrozen Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 7, 2025, 4:05 PM EST - 6 months ago

Surrozen Reports Third Quarter 2025 Financial Results and Provides Business Update

Sep 10, 2025, 11:30 AM EDT - 8 months ago

Surrozen Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 4:15 PM EDT - 8 months ago

Surrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 4, 2025, 8:00 AM EDT - 8 months ago

Surrozen Transcript: Cantor Global Healthcare Conference 2025

Aug 13, 2025, 7:00 AM EDT - 9 months ago

Surrozen Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 8, 2025, 4:05 PM EDT - 9 months ago

Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update

May 14, 2025, 8:30 AM EDT - 1 year ago

Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway

May 9, 2025, 4:05 PM EDT - 1 year ago

Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update

Mar 31, 2025, 4:05 PM EDT - 1 year ago

Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Mar 24, 2025, 9:00 AM EDT - 1 year ago

Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases

Nov 19, 2024, 2:25 PM EST - 1 year ago

Surrozen Transcript: Stifel 2024 Healthcare Conference

Nov 13, 2024, 3:00 PM EST - 1 year ago

Surrozen Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 6, 2024, 9:00 AM EST - 1 year ago

Surrozen Provides Third Quarter 2024 Financial Results and Business Update

Nov 4, 2024, 8:30 AM EST - 1 year ago

Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis

Sep 24, 2024, 8:30 AM EDT - 1 year ago

Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration

Aug 12, 2024, 4:05 PM EDT - 1 year ago

Surrozen Provides Second Quarter 2024 Financial Results and Business Update

Jun 12, 2024, 8:30 AM EDT - 2 years ago

Surrozen Publishes Study in ‘eLife' Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling

Jun 10, 2024, 8:30 AM EDT - 2 years ago

Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan

Jun 4, 2024, 8:30 AM EDT - 2 years ago

Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis

May 9, 2024, 8:30 AM EDT - 2 years ago

Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting

May 8, 2024, 4:05 PM EDT - 2 years ago

Surrozen Provides First Quarter 2024 Financial Results and Business Update

Apr 3, 2024, 8:40 AM EDT - 2 years ago

Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis

Apr 1, 2024, 8:30 AM EDT - 2 years ago

Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043

Apr 1, 2024, 8:30 AM EDT - 2 years ago

Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules

Jan 18, 2024, 8:30 AM EST - 2 years ago

Surrozen Provides Corporate Update on Clinical Programs

Nov 8, 2023, 4:05 PM EST - 2 years ago

Surrozen Provides Third Quarter 2023 Financial Results

Aug 9, 2023, 4:05 PM EDT - 2 years ago

Surrozen Provides Second Quarter 2023 Financial Results

Jun 5, 2023, 8:30 AM EDT - 3 years ago

Surrozen Publishes Study in Nature Communications Demonstrating the Promise of a Fzd4 Wnt Antibody in Treating Ischemic Stroke

May 10, 2023, 4:05 PM EDT - 3 years ago

Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates

Apr 5, 2023, 8:30 AM EDT - 3 years ago

Surrozen Strengthens Board of Directors with the Appointment of Eric Bjerkholt

Mar 22, 2023, 4:30 PM EDT - 3 years ago

Surrozen Earnings Call Transcript: Q4 2022

Mar 22, 2023, 4:01 PM EDT - 3 years ago

Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress

Mar 20, 2023, 4:30 PM EDT - 3 years ago

Surrozen To Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 22, 2023

Jan 4, 2023, 4:41 PM EST - 3 years ago

Surrozen to Present at the 41st Annual J.P. Morgan Healthcare Conference

Nov 14, 2022, 4:30 PM EST - 3 years ago

Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Oct 10, 2022, 8:00 AM EDT - 3 years ago

Surrozen Presents Data on Two Lead Therapeutic Candidates at United European Gastroenterology (UEG) Week

Oct 6, 2022, 8:00 AM EDT - 3 years ago

Surrozen Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agonist SZN-413 for People with Retinal Diseases

Sep 26, 2022, 8:00 AM EDT - 3 years ago

Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic Retinopathy

Aug 11, 2022, 8:00 AM EDT - 4 years ago

Surrozen Reports Second Quarter 2022 Financial Results

Jun 13, 2022, 8:00 AM EDT - 4 years ago

Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis

May 24, 2022, 8:00 AM EDT - 4 years ago

Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)

May 18, 2022, 8:00 AM EDT - 4 years ago

Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis

May 16, 2022, 8:00 AM EDT - 4 years ago

Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a Selective Wnt Mimetic, Stimulated Robust Colon Epithelial Regeneration and Ameliorated Colitis in an Acute Model of Inflammatory Bowel Dise

May 11, 2022, 8:00 AM EDT - 4 years ago

Surrozen Reports First Quarter 2022 Financial Results

May 5, 2022, 8:00 AM EDT - 4 years ago

Surrozen to Present at the BofA Securities 2022 Healthcare Conference

May 2, 2022, 8:00 AM EDT - 4 years ago

Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Mar 24, 2022, 8:00 AM EDT - 4 years ago

Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results

Jan 10, 2022, 8:00 AM EST - 4 years ago

Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline

Jan 5, 2022, 8:00 AM EST - 4 years ago

Surrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference

Nov 15, 2021, 4:00 PM EST - 4 years ago

Surrozen Reports Third Quarter 2021 Financial Results

Nov 15, 2021, 8:00 AM EST - 4 years ago

Surrozen to Present at The Piper Sandler 33rd Annual Healthcare Conference

Nov 15, 2021, 8:00 AM EST - 4 years ago

Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Meeting 2021, the Annual Meeting of the American Association for the Study of Liver Diseases

LabPsycho Apr. 24 at 7:30 PM

1 · Reply

BuyoutBobby Apr. 24 at 6:07 PM

$SRZN TCG's portfolio company Neurona Therapeutics was acquired recently.

1 · Reply

BuyoutBobby Apr. 24 at 8:36 AM

0 · Reply

BuyoutBobby Apr. 23 at 8:09 PM

0 · Reply

BuyoutBobby Apr. 23 at 7:10 PM

0 · Reply

Odintrading Apr. 22 at 2:03 PM

1 · Reply

BuyoutBobby Apr. 22 at 12:07 PM

1 · Reply

Quantumup Apr. 21 at 12:21 PM

0 · Reply

SocioCobb Apr. 16 at 1:32 PM

$SRZN 👍

2 · Reply

raticals Apr. 14 at 9:44 PM

0 · Reply

BuyoutBobby Apr. 14 at 8:03 PM

$SRZN with the share price getting higher and higher how is it possible that the tutes that hold the second tranche of the 2025 offering are not rushing to exercise these shares? They have the right with the optional closing option to exercise their full second tranche whenever they want. So they could get shares right now at a price of $11.6 while the stock trades around $30. Why are they not doing it and walk away with a nice profit? Sure that would crash the share price but they would make a profit anyway.

3 · Reply

Jw242 Apr. 14 at 8:00 PM

$SRZN umm. Ok. Do more of that 👌

0 · Reply

Jw242 Apr. 13 at 8:09 PM

$SRZN volume been on point. TCG may be loading still

2 · Reply

Quantumup Apr. 13 at 7:36 PM

William Blair reiterated $OCUL at an Outperform rating. $EYPT $SRZN $REGN RHHBY $KOD Here's whaat William Blair said in its note to investors: https://x.com/Quantumup1/status/2043774433601405234?s=20

0 · Reply

BuyoutBobby Apr. 9 at 7:54 PM

$SRZN did TCG buy some in the $25 area? We will know soon.

1 · Reply

SuperGreenToday Apr. 7 at 3:11 AM

$SRZN

0 · Reply

BuyoutBobby Apr. 5 at 11:40 AM

$SRZN What Chatgpt thinks what 2026 could happen:

1 · Reply

BuyoutBobby Apr. 2 at 6:43 PM

$SRZN another portfolio company of TCGX acquired by big pharma.

1 · Reply

wjmax Mar. 31 at 7:41 PM

$SRZN $NWBO Here might be the reason that TCG and Baker Brothers have investment in $SRZN. For a potent tolerogenic DC vaccine targeting autoimmunity or transplant tolerance, activating the β-catenin arm of the Wnt pathway is one of the most well-validated and mechanistically coherent strategies available.

1 · Reply

BuyoutBobby Mar. 31 at 11:58 AM

$SRZN there is more research from AntlerA which should also apply to our WNT drugs. https://pmc.ncbi.nlm.nih.gov/articles/PMC12330627/

1 · Reply

BuyoutBobby Mar. 29 at 5:01 PM

$SRZN there's a good chance that Merck wasn't the only company that wanted to acquire Eyebio. Merck won the bidding war and we don't know who lost it. But if they want another chance to get a WNT pipeline here we are with even better drugs.

0 · Reply

BuyoutBobby Mar. 28 at 12:12 PM

$SRZN the buying of TCGX also shows that they are ok with the MOA of the WNT drugs which seem to increase PDGFB signaling. The research was published March 17 so that could mean that TCG/TCGX knew about the mechanism of action already or they are ok with buying more even after knowing about it now.

0 · Reply

Market Cap	351.90M
Revenue (ttm)	3.48M
Net Income (ttm)	-242.03M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-6,954.89%
Debt to Equity Ratio	0.00

Volume	111,000
Avg Vol	100,668
Day's Range	N/A - N/A
Shares Out	11.49M
Stochastic %K	2%
Beta	0.52
Analysts	Strong Sell
Price Target	$38.75